Table 3

Unadjusted and adjusted continuous relationships between MRI ICVs and kidney disease phenotypes

MRI volume, adjusted for ICVKidney disease phenotype, analysis modelEstimate*SEP valuePredictor effect sizeAge effect size
CSF volumeeGFR, unadjusted−0.330.062.1 × 10−8
eGFR, adjusted−0.100.060.11−0.050.06
UACR, unadjusted0.140.060.02
UACR, adjusted0.130.060.020.030.06
CKD, unadjusted0.210.100.04
CKD, adjusted0.340.120.0060.370.06
GM volumeeGFR, unadjusted0.190.060.001
eGFR, adjusted−0.020.070.76−0.01−0.05
UACR, unadjusted−0.120.060.04
UACR, adjusted−0.140.060.03−0.03−0.05
CKD, unadjusted−0.220.100.03
CKD, adjusted−0.330.140.02−0.34−0.05
WM volumeeGFR, unadjusted0.140.060.02
eGFR, adjusted0.130.080.130.06−0.01
UACR, unadjusted−0.040.060.52
UACR, adjusted−0.020.080.78−0.004−0.01
CKD, unadjusted0.010.110.95
CKD, adjusted−0.020.170.92−0.02−0.01
WML volumeeGFR, unadjusted−0.290.062.2 × 10−6
eGFR, adjusted−0.090.070.23−0.020.03
UACR, unadjusted0.170.060.007
UACR, adjusted0.220.065.0 × 10−40.030.04
CKD, unadjusted0.280.110.009
CKD, adjusted0.450.140.0020.280.04
  • Adjustment reflects age, education, sex, BMI, HbA1c level, and hypertension.

  • * Estimate of the change in each MRI outcome corresponding to increases of 100 mg/g in UACR and 10 mL/min/1.73 m2 in eGFR, and the presence of CKD (vs. no CKD).